Enpatoran Demonstrates Sustained Benefits in Lupus Over 48 Weeks, suggests study

A new study published in EULAR Abstract Archive showed that following 48 weeks of therapy, enpatoran, an experimental Toll-like receptor (TLR) inhibitor, still has a good safety and tolerability profile in lupus patients.

For cutaneous lupus, standard medications frequently don't offer long-lasting relief. Enpatoran is a new oral dual TLR7/8 inhibitor that targets the interferon and immunological pathways that underlie lupus pathogenesis. This long-term extension trial assesses the 48-week safety, tolerability, and sustained effectiveness of enpatoran in patients with active cutaneous or systemic lupus after favorable Phase II (WILLOW) results showing considerable clinical improvement and excellent tolerability.

Patients with moderate-to-severe systemic lupus (Cohort B) and active cutaneous lupus (Cohort A) who finished the 24-week WILLOW trial were included in this double-blind long-term extension (LTE). While the previous placebo group converted to enpatoran 100 mg twice daily, the participants maintained their initial enpatoran regimens (25, 50, or 100 mg twice daily). A minimum 48-week course of treatment was followed by a 2-week safety check-in.

The presence of treatment-emergent adverse events (TEAEs), including treatment-related TEAEs and significant treatment-related TEAEs, from LTE Day 1 until the completion of safety follow-up was the main outcome. Exploratory efficacy endpoints included CLASI-50/70 responses, attainment of CLASI-A 0–3 at LTE Week 48, and least squares (LS) mean percentage change in CLASI-A score from WILLOW BL in participants with CLE or SLE with active cutaneous manifestations (CLASI-A ≥8) at WILLOW screening and BL.

Enpatoran (25 mg, 50 mg, and 100 mg) showed maintained safety and effectiveness in a long-term extension trial with 379 lupus patients (90.7% female, 86.7% SLE). 66.5–71.4% of patients experienced side events, mostly minor respiratory and urine infections; safety profiles were stable across dosages.

Trial discontinuations were uncommon, and treatment-related major adverse events were minimal (0–3.3%). For individuals with active cutaneous symptoms, efficacy was consistently maintained until Week 48.

The improvements of the original trial continued, and people who switched from a placebo also showed notable improvements. All dosing groups showed high clinical response rates; almost 60% of patients had practically clean skin (CLASI-A 0–3).

Overall, these results highlight the potential of enpatoran as a viable therapy option for individuals with cutaneous lupus, with or without systemic disease activity, by indicating that its effectiveness was maintained with prolonged treatment. To assess its long-term safety and effectiveness, more research is planned.

Reference:

E. Morand, S. Roy, R. Fernandez-Ruiz, H. Gühring, C. Kleinmond, Y. Wang, and J. Sanchez-Guerrero. SAFETY AND EFFICACY OF ENPATORAN IN LUPUS: RESULTS FROM THE FIRST 48 WEEKS OF THE PHASE II WILLOW LONG-TERM EXTENSION STUDY. Sparx-ip. EULAR Abstract Archive. https://scientific.sparx-ip.net/archiveeular/?view=1&c=a&searchfor=enpatoran&item=2026OP0337